

## Correction: *Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy*

Jiang X, Wang J, Zheng X, *et al.* Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy. *J Immunother Cancer* 2022;10:e003960. doi:10.1136/jitc-2021-003960

The author Jian Wang has had the following affiliation added: Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

*J Immunother Cancer* 2022;10:e003960corr1. doi:10.1136/jitc-2021-003960corr1

